PEG-Interferon lambda PEG-rIL-29: Phase IIa started

ZymoGenetics began the open-label, international Phase IIa EMERGE trial to evaluate multiple dose levels of subcutaneous PEG-Interferon lambda in 50 treatment-naïve patients. A double-blind Phase IIb ...